BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 12491054)

  • 21. Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.
    Ishiyama H; Satoh T; Kitano M; Tsumura H; Kotani S; Okusa H; Uemae M; Baba S; Hayakawa K
    Jpn J Clin Oncol; 2008 Jul; 38(7):469-73. PubMed ID: 18577509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contamination during a brachytherapy procedure.
    Caldwell C; Sankreacha R; Lightstone AW; O'Brien P; Matheson C
    Health Phys; 2007 Feb; 92(2 Suppl):S8-S12. PubMed ID: 17228191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques.
    Yamada Y; Potters L; Zaider M; Cohen G; Venkatraman E; Zelefsky MJ
    Am J Clin Oncol; 2003 Oct; 26(5):e130-5. PubMed ID: 14528087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Brachycurie therapy of tumors--renaissance of a radio-oncologic method].
    Sauer R; Thiel HJ; Müller R
    Fortschr Med; 1982 Jun; 100(22):1047-53. PubMed ID: 7106669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
    Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
    Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the actual state of industrial quality assurance procedures with regard to (106)Ru ophthalmic plaques.
    Kaulich TW; Zurheide J; Haug T; Budach W; Nüsslin F; Bamberg M
    Strahlenther Onkol; 2004 Jun; 180(6):358-64. PubMed ID: 15175870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Brachytherapy for prostate cancer].
    Yorozu A; Toya K; Ohashi T; Ohsuga K; Ito R; Kasamatsu T; Saito S; Momma T
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):424-7. PubMed ID: 16612148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
    Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
    Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
    Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
    Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
    Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of permanent prostate implants using automated delivery with seedSelectron versus manual insertion of RAPID Strands.
    Van Gellekom MP; Moerland MA; Wijrdeman HK; Battermann JJ
    Radiother Oncol; 2004 Oct; 73(1):49-56. PubMed ID: 15465145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality assurance of HDR prostate plans: program implementation at a community hospital.
    Rush JB; Thomas MD
    Med Dosim; 2005; 30(4):243-8. PubMed ID: 16275567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
    Glasgow GP; Dogan N; Mohideen N
    Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
    Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of CT- and radiograph-based post-implant dosimetry for transperineal 125I prostate brachytherapy using single seeds and a commercial treatment-planning software.
    Siebert FA; Kohr P; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):96-101. PubMed ID: 16447016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Well-ionization chamber response relative to NIST air-kerma strength standard for prostate brachytherapy seeds.
    Mitch MG; Zimmerman BE; Lamperti PJ; Seltzer SM; Coursey BM
    Med Phys; 2000 Oct; 27(10):2293-6. PubMed ID: 11099196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.